Anupam Rasayan India Ltd Credit Rating on Watch

Anupam Rasayan India Ltd's bank loan facilities (₹1,620 crore) and non-convertible debentures (₹160 crore) are now under 'Rating Watch with Developing Implications' by CRISIL Ratings. This follows the company's announcement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Ltd.

Reader Takeaway: Credit rating watch due to acquisition; revenue growth is positive, but margins and debt funding are key concerns.

What just happened

CRISIL Ratings has placed Anupam Rasayan India Ltd's debt facilities on watch due to its planned acquisition of a significant stake in Bliss GVS Pharma Ltd. The total rated debt amounts to ₹1,780 crore.

Why this matters

The 'Rating Watch with Developing Implications' signals uncertainty about the rating agency's future assessment. This could impact the company's borrowing costs and overall financial flexibility. Investors will be closely watching how the company manages the debt and integration related to the acquisition.

The backstory

Anupam Rasayan reported strong operational income growth, reaching ₹2,365.46 crore in FY 2026 from ₹1,438.72 crore in FY 2025. Profit After Tax (PAT) also increased to ₹222.20 crore from ₹159.85 crore. However, PAT margin slightly decreased to 9.39% from 11.11% during the same period. Adjusted debt to net worth rose to 0.54 from 0.45, and interest coverage remained stable at 3.53 times.

The company's operating margins declined to 22.19% in FY 2026 from 27.67% in FY 2025, attributed to an inability to fully pass on costs. Gross current assets remained high at 504 days as of March 31, 2026. Over 50% of Anupam Rasayan's revenue comes from exports, making it susceptible to forex volatility.

What changes now

The acquisition of Bliss GVS Pharma Ltd involves ₹300 crore in debt and the balance via non-controlling, non-voting equity. CRISIL will assess the capital allocation for this acquisition as a critical factor.

Risks to watch

Key risks include the impact of the acquisition's debt funding on leverage ratios, the company's ability to manage working capital, and the persistence of operating margin pressure due to cost pass-on limitations. Forex volatility also remains a concern.

Peer comparison

(No peer comparison data available in the provided filing.)

Context metrics (time-bound)

• FY 2026 Operating Income: ₹2,365.46 crore (vs. ₹1,438.72 crore in FY 2025)
• FY 2026 PAT: ₹222.20 crore (vs. ₹159.85 crore in FY 2025)
• FY 2026 PAT Margin: 9.39% (vs. 11.11% in FY 2025)
• FY 2026 Adjusted Debt/Net Worth: 0.54x (vs. 0.45x in FY 2025)
• FY 2026 Interest Coverage: 3.53x (vs. 3.55x in FY 2025)
• FY 2026 Operating Margins: 22.19% (vs. 27.67% in FY 2025)
• Working Capital: 504 days (as of March 31, 2026)
• Total Rated Debt: ₹1,780 crore (₹1,620 crore bank loans + ₹160 crore NCDs)

What to track next

Investors should monitor future updates on the funding structure of the Bliss GVS Pharma acquisition and its integration progress. The company's ability to maintain leverage below 0.80x (TOLANW) and manage liquidity will be crucial for the rating resolution.